{"transactions":[{"id":934431,"issuer":{"id":7639,"kind":"organization","name":"Neuphoria Therapeutics Inc."},"owners":[{"id":69065,"kind":"person","name":"Davies Peter Miles Winston","position":1,"cik":"0002030200","reported_name":"Davies Peter Miles Winston","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2026-01-21T16:01:30.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":8537,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The grant of RSUs is pursuant to the Company's Board of Directors annual remuneration policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person's continuous service to the Company through the first of the following dates: (a) the day prior to the Company' next annual shareholder meeting (which is expected to be no later than December 15, 2026) or (b) the effective date of a Change in Control of the Company, the RSUs shall fully vest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the Reporting Person's continuous service to the Company through the first of the following dates: (a) the day prior to the Company' next annual shareholder meeting (which is expected to be no later than December 15, 2026) or (b) the effective date of a Change in Control of the Company, the RSUs shall fully vest."}],"balance_after":15320,"derivative":{"underlying":"Common Stock","underlying_shares":8537},"source":{"system":"sec-edgar","filing":"0001213900-26-006171","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2030200/000121390026006171/ownership.xml","form_type":"4"}},{"id":1169144,"issuer":{"id":7639,"kind":"organization","name":"Neuphoria Therapeutics Inc."},"owners":[{"id":69065,"kind":"person","name":"Davies Peter Miles Winston","position":1,"cik":"0002030200","reported_name":"Davies Peter Miles Winston","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-04-18T08:03:03.000Z","date":"2025-04-16","kind":"grant","planned":false,"acquired":true,"shares":6783,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to the Reporting Person's continuous service to the Company through the day prior to the Company' next annual shareholder meeting (which is expected to be no later than November 30, 2025), the RSUs shall fully vest at 5:01 PM EST on the day prior to the Company's next annual shareholder meeting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to the Reporting Person's continuous service to the Company through the day prior to the Company' next annual shareholder meeting (which is expected to be no later than November 30, 2025), the RSUs shall fully vest at 5:01 PM EST on the day prior to the Company's next annual shareholder meeting."}],"balance_after":6783,"derivative":{"underlying":"Common Stock","underlying_shares":6783},"source":{"system":"sec-edgar","filing":"0001213900-25-033143","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2030200/000121390025033143/ownership.xml","form_type":"4"}}]}